TR199902766T2 - Proteaz inhibitörleri. - Google Patents

Proteaz inhibitörleri.

Info

Publication number
TR199902766T2
TR199902766T2 TR1999/02766T TR9902766T TR199902766T2 TR 199902766 T2 TR199902766 T2 TR 199902766T2 TR 1999/02766 T TR1999/02766 T TR 1999/02766T TR 9902766 T TR9902766 T TR 9902766T TR 199902766 T2 TR199902766 T2 TR 199902766T2
Authority
TR
Turkey
Prior art keywords
protease inhibitors
keto
hydroxy
inhibitors
cyclohetero
Prior art date
Application number
TR1999/02766T
Other languages
English (en)
Inventor
D. Gribble Andrew
Witherington Jason
Edward Fenwick Ashley
Frank Veber Daniel
W. Marquis Robert
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of TR199902766T2 publication Critical patent/TR199902766T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Bu bulus, özellikle katepsin K olmak üzere sistein proteazlarinin inhibitörleri olan ve kemik kaybinin bir faktör oldugu hastaliklarin tedavisinde faydali olan 3-hidroksi ve 3-keto-siklohetero-ikameli lösin bilesikleri ile ilgilidir. 3-hidroksi-veya 3-keto-kismi bir tetrahidrotiofen, tetrahidrotiopiran, tetrahidrofuran veya tetrahidropiran halkasina baglanir.
TR1999/02766T 1997-05-06 1998-05-06 Proteaz inhibitörleri. TR199902766T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4575897P 1997-05-06 1997-05-06

Publications (1)

Publication Number Publication Date
TR199902766T2 true TR199902766T2 (tr) 2000-02-21

Family

ID=21939723

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02766T TR199902766T2 (tr) 1997-05-06 1998-05-06 Proteaz inhibitörleri.

Country Status (19)

Country Link
EP (1) EP1003846A4 (tr)
JP (1) JP2001525804A (tr)
KR (1) KR20010012256A (tr)
CN (1) CN1255161A (tr)
AR (1) AR013079A1 (tr)
AU (1) AU7562598A (tr)
BR (1) BR9809306A (tr)
CA (1) CA2288868A1 (tr)
CO (1) CO4950618A1 (tr)
HU (1) HUP0002247A3 (tr)
IL (1) IL132088A0 (tr)
NO (1) NO995434L (tr)
NZ (1) NZ337889A (tr)
PE (1) PE71599A1 (tr)
PL (1) PL336856A1 (tr)
TR (1) TR199902766T2 (tr)
UY (1) UY25143A1 (tr)
WO (1) WO1998050533A1 (tr)
ZA (1) ZA983762B (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
DZ3083A1 (fr) * 1999-02-19 2004-06-02 Smithkline Beecham Corp Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
WO2001034599A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
EP1326848A1 (en) * 2000-10-19 2003-07-16 Naeja Pharmaceutical Inc. Dihydropyrimidine derivatives as cysteine protease inhibitors
IL155961A0 (en) * 2000-11-17 2003-12-23 Medivir Uk Ltd Cysteine protease inhibitors
EP1358183B1 (en) * 2000-11-17 2006-04-12 Medivir Ab Cysteine protease inhibitors
WO2002057270A1 (en) 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
CA2434068A1 (en) * 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
NZ526914A (en) * 2001-01-17 2005-02-25 Amura Therapeutics Ltd Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
US6841571B2 (en) * 2001-10-29 2005-01-11 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
BR0312662A (pt) * 2002-07-16 2005-05-03 Amura Therapeutics Ltd Compostos biologicamente ativos
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
CA2900181C (en) 2003-08-06 2019-01-29 Catherine Tachdjian Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
AU2016206281B2 (en) * 2003-08-06 2017-11-30 Senomyx, Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
WO2005066180A1 (en) * 2004-01-08 2005-07-21 Medivir Ab Cysteine protease inhibitors
CA2619706A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
MX2009012847A (es) * 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
GB0817424D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3190431B2 (ja) * 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
JPH05140063A (ja) * 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
JP3599287B2 (ja) * 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
US5403952A (en) * 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
AU711014B2 (en) * 1995-10-30 1999-10-07 Smithkline Beecham Corporation Method of inhibiting cathepsin K
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
WO1998004539A1 (fr) * 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes

Also Published As

Publication number Publication date
HUP0002247A3 (en) 2003-01-28
CA2288868A1 (en) 1998-11-12
AU7562598A (en) 1998-11-27
NO995434D0 (no) 1999-11-05
AR013079A1 (es) 2000-12-13
KR20010012256A (ko) 2001-02-15
CN1255161A (zh) 2000-05-31
CO4950618A1 (es) 2000-09-01
HUP0002247A2 (hu) 2001-05-28
WO1998050533A1 (en) 1998-11-12
NZ337889A (en) 2001-09-28
PL336856A1 (en) 2000-07-17
BR9809306A (pt) 2000-07-04
NO995434L (no) 1999-11-05
IL132088A0 (en) 2001-03-19
EP1003846A4 (en) 2002-11-13
EP1003846A1 (en) 2000-05-31
PE71599A1 (es) 1999-09-15
ZA983762B (en) 1998-11-06
UY25143A1 (es) 1998-11-27
JP2001525804A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
TR199902766T2 (tr) Proteaz inhibitörleri.
SE0201980D0 (sv) Novel compounds
ATE193304T1 (de) Inhibitoren der menschlichen neutrophilenelastase
HUP0303143A2 (hu) A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
DE69637307D1 (de) Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
ATE409482T1 (de) Cathepsincystein-proteasehemmer
IL160295A0 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
TR199902751T2 (tr) Proteaz inhibitörleri.
TR199902692T2 (tr) Serin proteaz inhibitörleri.
HUP0402162A2 (hu) A humán angiopoietin-2 specifikus kötőanyagai
DE69835532D1 (de) Quinolin-enthaltende alpha-ketoamid-basierte inhibitoren von cystein- und serin protease
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
HK1025511A1 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
ATE253920T1 (de) Phosphor enthaltende hemmer von cystein- und serin-proteasen
HUP0402165A2 (hu) Nem neurotoxikus plazminogén aktiváló faktorok a szélhűdés kezelésére
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
SE0203712D0 (sv) Novel compounds
HUP0400976A2 (hu) VII-es faktor polipeptideket és XI-es faktor polipeptideket tartalmazó gyógyszerészeti összetételek
AR021241A1 (es) Inhibidores de proteasas
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
DE60031422D1 (de) Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
WO2002057248A3 (en) Inhibitors of cruzipain and other cysteine proteases
DE69310517T2 (de) Zytotoixisches t- lymphozyten antigen als cystein protease inhibitor